Liwei Wang
Impact in
- Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cytokine Signaling Pathways and Interactions
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
- Oncology 56
- Pancreatic and Hepatic Oncology Research 20
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 9
- CAR-T cell therapy research 6
-
- Kruppel-like factors research 6
- Epigenetics and DNA Methylation 6
- Co-authors
- Keping Xie (10 shared papers)Daoyan Wei (7 shared papers)Xiangdong Le (7 shared papers)Suyun Huang (5 shared papers)Weihua Jiang (6 shared papers)Jiujie Cui (14 shared papers)Hai Hu (9 shared papers)Weiyi Huang (6 shared papers)
- Journals
- Journal of Clinical Oncology (17 papers)Oncotarget (7 papers)Cancer Research (5 papers)Tumor Biology (3 papers)Current Pharmaceutical Design (3 papers)
- Partner nations
- ChinaUnited StatesSpain
In The Last Decade
Liwei Wang
109 papers receiving 3.9k citations
Liwei Wang's Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 1.7k
- Cancer Research 675
- Molecular Biology 1.7k
- Pathology and Forensic Medicine 367
- Pulmonary and Respiratory Medicine 543
Countries citing papers authored by Liwei Wang
This map shows the geographic impact of Liwei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwei Wang more than expected).
Fields of papers citing papers by Liwei Wang
This network shows the impact of papers produced by Liwei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwei Wang. The network helps show where Liwei Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Liwei Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 113 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 567 |
| 2 | 2003 | 466 | |
| 3 | 2014 | 186 | |
| 4 | 2011 | 148 | |
| 5 | 2016 | 140 | |
| 6 | 2009 | 129 | |
| 7 | 2012 | 125 | |
| 8 | Prognostic value of CRM1 in pancreas cancer. | 2009 | 124 |
| 9 | 2005 | 122 | |
| 10 | 2013 | 88 | |
| 11 | 2011 | 86 | |
| 12 | 2015 | 86 | |
| 13 | 2016 | 75 | |
| 14 | 2016 | 74 | |
| 15 | 2010 | 69 | |
| 16 | 2017 | 67 | |
| 17 | 2010 | 63 | |
| 18 | 2015 | 58 | |
| 19 | 2004 | 57 | |
| 20 | 2015 | 54 |
About Liwei Wang
Liwei Wang is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 113 papers that have together received 4.0k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (20 papers), Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (8 papers), Kruppel-like factors research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Epigenetics and DNA Methylation (6 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (675 citations), Molecular Biology (1.7k citations), Pathology and Forensic Medicine (367 citations) and Pulmonary and Respiratory Medicine (543 citations). Liwei Wang has collaborated with scholars based in China, United States and Spain. Frequent co-authors include Keping Xie, Daoyan Wei, Xiangdong Le, Suyun Huang, Weihua Jiang, Jiujie Cui, Hai Hu, Weiyi Huang, Ziliang Jin and Ting Han. Their work appears in journals such as Journal of Clinical Oncology, Oncotarget, Cancer Research, Tumor Biology and Current Pharmaceutical Design.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.